Zum Hauptinhalt springen
| Hans-Günter Meyer-Thompson | Buprenorphin

Clinical trial for opioid therapy moves closer to market

A multi-site clinical trial led by researchers at the University of Kentucky Center on Drug and Alcohol Research (CDAR) has demonstrated the effectiveness of CAM2038, a potentially transformative buprenorphine therapy for moderate-to-severe opioid use disorders. (medicalxpress, 24.01.2017)

https://medicalxpress.com/news/2017-01-clinical-trial-opioid-therapy-closer.html